Bio Rad Laboratories Inc Revenue Growth Rates (BIO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Bio rad Laboratories Inc   (NYSE: BIO)
 

BIO's Revenue Growth by Quarter and Year

Bio Rad Laboratories Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BIO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 651.00
1st Quarter March 591.40
FY 1,242.40

BIOs Annual Revenue
Bio Rad Laboratories Inc 's Revenue in the fiscal year 2025 $ 2,582.90 millions
Bio Rad Laboratories Inc 's Revenue in the fiscal year 2024 $ 2,565.90 millions
Bio Rad Laboratories Inc 's Revenue in the fiscal year 2023 $ 2,670.95 millions
Bio Rad Laboratories Inc 's Revenue in the fiscal year 2022 $ 2,802.25 millions
Bio Rad Laboratories Inc 's Revenue in the fiscal year 2021 $ 2,922.55 millions




BIO Revenue second quarter 2026 Y/Y Growth Comment
Bio Rad Laboratories Inc reported decrease in Revenue in the second quarter 2026 by -0.05% to $ 651.00 millions, from the same quarter in 2025.
The decrease in the second quarter 2026 Bio Rad Laboratories Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 2.36%.

Looking into second quarter 2026 results within Laboratory Analytical Instruments industry 15 other companies have achieved higher Revenue growth. While Bio Rad Laboratories Inc ' s Revenue decline of -0.05% ranks overall at the positon no. 2790 in the second quarter 2026.


BIO Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 3.78 % -1.91 % -6.62 %
3rd Quarter September - 0.54 % 2.73 % -7.22 %
2nd Quarter June -0.05 % 2.07 % -6.23 % -1.54 %
1st Quarter March 1.09 % -4.09 % -9.88 % -3.32 %
FY   - 0.66 % -3.93 % -

Financial Statements
Bio Rad Laboratories Inc 's second quarter 2026 Revenue $ 651.00 millions BIO's Income Statement
Bio Rad Laboratories Inc 's second quarter 2025 Revenue $ 651.30 millions Quarterly BIO's Income Statement


BIO Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 6.41 % 3.08 % 7.96 %
3rd Quarter September - 0.17 % 1.69 % -7.17 %
2nd Quarter June 10.08 % 11.33 % 4.61 % 0.54 %
1st Quarter March -14.81 % -12.54 % -10.55 % -7.32 %
FY (Year on Year)   - 0.66 % -3.93 % -


Back to BIO Growth rate Comparisons >> Back to BIO Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #16
Healthcare Sector #397
Overall #2790

Revenue Y/Y Growth Statistics
High Average Low
33.35 % 2.36 % -11.44 %
(Jun 30 2021)   (Jun 30 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #16
Healthcare Sector #397
Overall #2790
Revenue Y/Y Growth Statistics
High Average Low
33.35 % 2.36 % -11.44 %
(Jun 30 2021)   (Jun 30 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Bio Rad Laboratories Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
22.03 % 1.15 % -20.96 %
(Dec 31 2020)  


BIO's II. Quarter Q/Q Revenue Comment
Bio rad Laboratories Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 10.08%, to $ 651.00 millions, from $591.40 millions in the first quarter.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Bio Rad Laboratories Inc 's Revenue growth quarter on quarter, overall rank is 820.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #124
Overall #820
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #124
Overall #820
Revenue Q/Q Growth Statistics
High Average Low
22.03 % 1.15 % -20.96 %
(Dec 31 2020)  


BIO's II. Quarter Q/Q Revenue Comment
Bio rad Laboratories Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 10.08%, to $ 651.00 millions, from $591.40 millions in the first quarter.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Bio Rad Laboratories Inc 's Revenue growth quarter on quarter, overall rank is 820.


Bio Rad Laboratories Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 2,589.00 $ 2,589.30 $ 2,582.90 $ 2,557.61 $ 2,554.12
Y / Y Revenue Growth (TTM) 1.37 % 1.9 % 0.66 % -0.83 % -0.3 %
Year on Year Revenue Growth Overall Ranking # 2494 # 2546 # 1639 # 1796 # 1094
Seqeuential Revenue Change (TTM) -0.01 % 0.25 % 0.99 % 0.14 % 0.52 %
Seq. Revenue Growth (TTM) Overall Ranking # 2582 # 2422 # 1473 # 1466 # 951


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Bio Rad Laboratories Inc 's cumulative twelve months Revenue were $ 2,589 millions, company would post below average annual Revenue growth of 0.52% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Bio Rad Laboratories Inc 's Revenue growth from the 591.4% growth in Mar 31 2026.

In the Healthcare sector 360 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2494, from total ranking in previous quarter at 2546.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 16
Healthcare Sector # 361
Overall # 2494

Revenue TTM Y/Y Growth Statistics
High Average Low
25.56 %
 1.9 %
-7.47 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 373
S&P 500 # 2582
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Bio Rad Laboratories Inc 's cumulative twelve months Revenue were $ 2,589 millions, company would post below average annual Revenue growth of -7.47% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Bio Rad Laboratories Inc 's Revenue growth from the 591.4% growth in Mar 31 2026.

In the Healthcare sector 360 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2494, from total ranking in previous quarter at 2546.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 16
Healthcare Sector # 361
Overall # 2494

Revenue TTM Y/Y Growth Statistics
High Average Low
25.56 %
1.9 %
-7.47 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 373
S&P 500 # 2582




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BIO's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Bio Rad Laboratories Inc Revenue Growth Rates (BIO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Bio Rad Laboratories Inc (CIK 12208).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000012208-26-000048
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Bio Rad Laboratories Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.